<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/223067-injection-solution-of-an-lhrh-antagonist by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 06:55:13 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 223067:INJECTION SOLUTION OF AN LHRH ANTAGONIST</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">INJECTION SOLUTION OF AN LHRH ANTAGONIST</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Aqueous injection solution of an LHRH antagonist containing gluconic acid, a bulking agent and optionally a surfactant, characterized in that cetrorelix, teverelix, D-63153 (Ac-D-Nal-pCI-D-Phe-3-D-Pal-Ser-N-Me-Tyr-D-H-Cit-Nle-Arg- Pro-D-Ala-NH2), ganirelix, abarelix, antide, or azaline B is used as LHRH antagonist and in that gluconic acid is present in a more than equimolar amount, based on the amount of LHRH antagonist, in that gluconic acid is added in the form of gluconic acid delta-lactone, in that mannitol is used as bulking agent and in that, optionally, Tween 80 is added as surfactant.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>Injection solution of an LHRH antagonist<br>
Technical field:<br>
The invention relates to aqueous injection solutions of an LHRH antagonist<br>
using additions of organic, physiologically tolerable acids and/or surfactants<br>
and their preparation for prevention of the aggregation of the LHRH<br>
antagonist in solution. The injection solutions prepared according to the<br>
invention additionally lead to an increase in the bioavailabiiity and make<br>
possible the lowering of the injection volume to be administered.<br>
Prior art:<br>
In controlled ovarian stimulation followed by egg cell removal and<br>
techniques of assisted reproduction, besides LHRH agonists (e.g.<br>
triptorelin, buserelin), LHRH antagonists (cetrorelix, ganirelix) have<br>
especially been used for some time, since they avoid the initial increase in<br>
endogenous gonadotropin secretion and immediately lead to a competitive<br>
inhibition of gonadotropin-releasing hormone [EP 0 788 799 A2; EP 0 299<br>
402 B1]. The LHRH antagonist ganirelix is at present used in a formulation<br>
which contains 0.25 mg of ganirelix in 0.5 ml of an aqueous, mannitol-<br>
containing solution in the form of a ready-to-use injection (Orgalutran®).<br>
The LHRH antagonist cetrorelix (Cetrotide®) is at present supplied in two<br>
administration forms: a lyophilizate containing 0.25 mg of cetrorelix<br>
combined with a ready-to-use syringe which contains 1 ml of water for<br>
reconstitution, and a lyophilizate containing 3 mg of cetrorelix combined<br>
with a ready-to-use syringe which contains 3 ml of water for reconstitution.<br>
LHRH antagonists, however, are not only used for controlled ovarian<br>
stimulation, but can also be used for the therapy of hormone-dependent<br>
types of cancer such as, for example, prostate carcinoma. Substances<br>
such as abarelix [WO 98/25642] or cetrorelix [WO 00/47234] could be used<br>
for this in that the LHRH antagonists could be an alternative to the market-<br>
dominating agonists (leuprolide, goserelin) in this therapy. On account of<br>
the relatively poor solubility of abarelix in water or physiological media, a<br>
depot formulation must be used in order to achieve a long-term action.<br>
There are indications, however, that a long-term action could also be<br>
caused by good solubility of the LHRH antagonists [G. Jiang, J. Stakewski,<br>
R. Galyean, J. Dykert, C. Schteingart, P. Broqua, A. Aebi, M. L. Aubert,<br>
G. Semple, P. Robson, K. Akinsanya, R. Haigh, P. Riviere, J. Trojnar,<br>
J. L. Junien and J. E. Rivier, J. Med. Chem., 2001, 44, 453-467].<br>
Presentation of the invention:<br>
It is the object of the invention to prepare an injection solution which<br>
achieves a low injection volume together with an increased concentration<br>
of the LHRH antagonist by means of its improved solubility. At the same<br>
time, the aggregation of the LHRH antagonist in the relatively highly<br>
concentrated injection solution should be prevented.<br>
It has surprisingly been found that organic, physiologically tolerable acids,<br>
particularly carboxylic acids, in particular hydroxycarboxylic acids, but<br>
preferably gluconic acid on its own or in combination with surfactants such<br>
as, for example, Tween, markedly improve the solubility of LHRH<br>
antagonists and thus markedly reduce the proneness to aggregation of<br>
these substances.<br>
The invention therefore makes it possible to prepare LHRH antagonists in<br>
relatively high concentration in aqueous solutions for injection. LHRH<br>
antagonists which may be mentioned are, for example, cetrorelix, teverelix,<br>
D-63 153 (Ac-D-Nal-pCI-D-Phe-3-D-Pal-Ser-N-Me-Tyr-D-H-Cit-lso-Leu-<br>
Arg-Pro-D-Ala-NH2) ganirelix, abarelix, antide, azaline B. It was seen that<br>
an excess of the respective carboxylic acid must be used; equimolar<br>
amounts are not sufficient. Obviously, this effect cannot be explained alone<br>
by an in-situ salt formation with basic amino acid residues present such as,<br>
for example, arginine, pyridylalanine, lysine. Likewise, the surfactant<br>
concentration must not be chosen to be too high, since otherwise the<br>
solutions foam too much and aggregation is in turn induced by the<br>
surfactants.<br>
At the same time, these additions make possible an increase in the<br>
bioavailability, since they obviously also slow the spontaneous aggregation<br>
in the body after injection or make possible a more rapid absorption of the<br>
substance from the site of action. It was seen that the lowered pH of such<br>
injection solutions (e.g. pH = 2.5-3) has no influence on the local tolerability<br>
of the injection. By increasing the concentration, it is possible to reduce the<br>
volume administered, e.g. in the case of cetrorelix from 3 ml to 1 ml for the<br>
3 mg form. It was likewise shown that by means of these additions a good<br>
storage stability can be achieved (see Example 1). Although storage for<br>
over 6 months at 25°C/60% produced an increase in the impurities, the<br>
content value in each case was still clearly above 90% (as a rule the lowest<br>
value of the use period specification of pharmaceutical products). The<br>
turbidity, as a sign of aggregation, increased only slightly. Turbidity values<br>
of up to 8 FTU (formazine turbidity unit according to European<br>
Pharmacopoeia) are perfectly tolerable.<br>
Preservatives such as, for example, phenol or p-chloro-m-cresol do not<br>
interfere and can additionally be used for the preservation of the solutions.<br>
The use of customary bulking agents, such as mannitol, lactose, glucose<br>
and fructose, is likewise possible.<br>
Description of a route for carrying out the invention:<br>
were mixed with water for injection to 2 litres to give a homogeneous<br>
solution. The solution was then sterile-filtered and dispensed into<br>
ampoules. The ampoules were investigated analytically for purity (HPLC),<br>
content (HPLC), pH and aggregation (turbidity) initially and after a storage<br>
time of 6 months at 2-8°C and 25°C/60% rel. humidity.<br>
Example 2<br>
About 500 mg of D-63153<br>
About 100 mg of Tween 80<br>
About 475 mg of mannitol<br>
were adjusted to a pH of about 2.5 using aqueous, saturated gluconic acid<br>
delta-lactone solution. A volume of about 50 ml resulted. The mixture was<br>
stirred until a clear solution resulted.<br>
Analytical results:<br>
The turbidity of the solution was initially 2.4 FTU. After 24 h, 2.1 FTU were<br>
measured. The purity profile and the content of the solution (HPLC)<br>
remained unchanged.<br>
Structure of the LHRH antagonist D-63153:<br>
Ac-D-Nal-pCI-D-Phe-3-D-Pal-Ser-N-Me-Tyr-D-H-Cit-lso-Leu-Arg-Pro-D-<br>
Ala-NH2<br>
Example 3<br>
About 100 mg of teverelix<br>
About 100 mg of Tween 80<br>
About 475 mg of mannitol<br>
were adjusted to a pH of about 2.5 using aqueous, saturated gluconic acid<br>
delta-lactone solution. A volume of about 10 ml resulted. The mixture was<br>
stirred until a clear solution resulted.<br>
Analytical results:<br>
The turbidity of the solution was initially 6.8 FTU. After 24 h, 8.4 FTU were<br>
measured. The purity profile and the content of the solution (HPLC)<br>
remained unchanged.<br>
Structure of the LHRH antagonist teverelix:<br>
Ac-D-Nal-pCI-D-Phe-3-D-Pal-Ser-Tyr-D-H-Cit-Leu-iPr-Lys-Pro-D-Ala-NH2<br>
WE CLAIM:<br>
1. Aqueous injection solution of an LHRH antagonist containing gluconic<br>
acid, a bulking agent and optionally a surfactant, characterized in that<br>
cetrorelix, teverelix, D-63153 (Ac-D-Nal-pCI-D-Phe-3-D-Pal-Ser-N-Me-Tyr-<br>
D-H-Cit-Nle-Arg-Pro-D-Ala-NH2), ganirelix, abarelix, antide, or azaline B is<br>
used as LHRH antagonist and in that gluconic acid is present in a more<br>
than equimolar amount, based on the amount of LHRH antagonist, in that<br>
gluconic acid is added in the form of gluconic acid delta-lactone, in that<br>
mannitol is used as bulking agent and in that, optionally, Tween 80 is<br>
added as surfactant.<br>
2. Aqueous injection solution of an LHRH antagonist as claimed in claim 1,<br>
further containing Tween 80 as surfactant.<br>
3. Aqueous injection solution of an LHRH antagonist as claimed in claim 1,<br>
comprising<br>
500 mg cetrorelix<br>
2,4 g gluconic acid delta-lactone<br>
2,0 g Tween 80<br>
95,0 g mannitol<br>
in 2 L water for injection.<br>
4. Aqueous injection solution of an LHRH antagonist as claimed in claim 1,<br>
comprising<br>
500 mg D-63153<br>
100 mg Tween 80<br>
475 mg mannitol<br>
adjusted to 50 ml_ using saturated gluconic acid delta-lactone solution.<br>
5. Aqueous injection solution of an LHRH antagonist as claimed in claim 1,<br>
comprising<br>
100 mg teverelix<br>
100 mg Tween 80<br>
475 mg mannitol<br>
adjusted to 10 mL using saturated gluconic acid delta-lactone solution.<br>
6. Process for the preparation of aqueous injection solutions of an LHRH<br>
antagonist as claimed in any one of claims 1 to 5, wherein, alternatively<br>
- an LHRH antagonist, gluconic acid in the form of gluconic acid delta-<br>
lactone, the gluconic acid being present in a more than equimolar<br>
amount based on the amount of LHRH antagonist, mannitol as bulking<br>
agent and, optionally, Tween 80 as surfactant are dissolved in water<br>
for injection, homogenized and processed for injection purposes; or<br>
an LHRH antagonist, mannitol as bulking agent and, optionally, Tween<br>
80 as surfactant and are dissolved using an aqueous saturated<br>
solution of gluconic acid delta-lactone, homogenized and processed for<br>
injection purposes.<br>
Aqueous injection solution of an LHRH antagonist containing gluconic acid, a<br>
bulking agent and optionally a surfactant, characterized in that cetrorelix,<br>
teverelix, D-63153 (Ac-D-Nal-pCI-D-Phe-3-D-Pal-Ser-N-Me-Tyr-D-H-Cit-Nle-Arg-<br>
Pro-D-Ala-NH2), ganirelix, abarelix, antide, or azaline B is used as LHRH<br>
antagonist and in that gluconic acid is present in a more than equimolar amount,<br>
based on the amount of LHRH antagonist, in that gluconic acid is added in the<br>
form of gluconic acid delta-lactone, in that mannitol is used as bulking agent and<br>
in that, optionally, Tween 80 is added as surfactant.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LUtPTE5QLTIwMDQtKDA2LTEyLTIwMTIpLUZPUk0tMjcucGRm" target="_blank" style="word-wrap:break-word;">667-KOLNP-2004-(06-12-2012)-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LUtPTE5QLTIwMDQtRk9STSAyNy5wZGY=" target="_blank" style="word-wrap:break-word;">667-KOLNP-2004-FORM 27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LUtPTE5QLTIwMDQtRk9STS0yNy0xLnBkZg==" target="_blank" style="word-wrap:break-word;">667-KOLNP-2004-FORM-27-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LUtPTE5QLTIwMDQtRk9STS0yNy5wZGY=" target="_blank" style="word-wrap:break-word;">667-KOLNP-2004-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1jb3JyZXNwb25kZW5jZS5wZGY=" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1kZXNjcmlwdGlvbiAoY29tcGxldGUpLnBkZg==" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1leGFtaW5hdGlvbiByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1mb3JtIDE4LnBkZg==" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1mb3JtIDIucGRm" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1mb3JtIDI2LnBkZg==" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-form 26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1yZXBseSB0byBleGFtaW5hdGlvbiByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC1zcGVjaWZpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-specification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=NjY3LWtvbG5wLTIwMDQtZ3JhbnRlZC10cmFuc2xhdGVkIGNvcHkgb2YgcHJpb3JpdHkgZG9jdW1lbnQucGRm" target="_blank" style="word-wrap:break-word;">667-kolnp-2004-granted-translated copy of priority document.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="223066-an-audio-decoder-and-an-audio-decoding-method-thereof.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="223068-inhibitors-of-cytosolic-phospholipase-a2.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>223067</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>667/KOLNP/2004</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>36/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>05-Sep-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>03-Sep-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>21-May-2004</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>ZENTARIS GMBH</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>WEISMULLERSTRASSE 45, 60314 FRANKFURT</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>BAUER, HORST</td>
											<td>ROHRENSTRAâE 12A 91217 HERSBRUCK</td>
										</tr>
										<tr>
											<td>2</td>
											<td>RISCHER, MATTHIAS</td>
											<td>SCHLESIERSTR. 20 60388 FRANKFURT</td>
										</tr>
										<tr>
											<td>3</td>
											<td>ENGEL, JÜRGEN</td>
											<td>ERLENWEG 3 63755 ALZENAU</td>
										</tr>
										<tr>
											<td>4</td>
											<td>GÜTHLEIN, FRANK</td>
											<td>WESTENDSTRAßE 5 63477 MAINTAL</td>
										</tr>
										<tr>
											<td>5</td>
											<td>DI STEFANO, DOMINIQUE</td>
											<td>AM BÖRNCHEN 14 65479 RAUNHEIM</td>
										</tr>
										<tr>
											<td>6</td>
											<td>SARLIKIOTIS, WERNER</td>
											<td>SP. DIMA 31 19002 PEANIA GRIECHENLAND</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 38/09</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP02/12798</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2002-11-15</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>101 57 628.5</td>
									<td>2001-11-26</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/223067-injection-solution-of-an-lhrh-antagonist by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 06:55:14 GMT -->
</html>
